"Our common goal is to improve the management of critically ill patients with first-in-class diagnostics and targeted therapy." Dr. Andreas Bergmann, founder of the Medicine4Future Initiative
The companies of the Medicine4Future Initiative, SphingoTec GmbH, 4TEEN4 Pharmaceuticals GmbH, Adrenomed AG and Nexus Dx Inc., have the common goal to improve the management of critically ill patients and in future help preventing the manifestation of common diseases by developing first-in-class diagnostics and targeted therapies in a hypothesis-driven approach that is deeply rooted in a profound understanding of disease biology. Starting from assay development and growing evidence from large cohort studies, blood biomarkers are associated with relevant patient outcomes in underserved medical conditions. Based on data that prove that a biomarker can reliably monitor outcomes, antibodies are subsequently developed to validate if the biomarker also represents a druggable target. If so, drug candidates are tested in appropriate pre-clinical models and consecutively enter first in-men clinical trials. The Medicine4Future Initiative was established by Dr. Andreas Bergmann, one of the founders and former Chief Scientific Officer of B.R.A.H.M.S. AG where he was responsible for the development of the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).